Normal Lactate Dehydrogenase Does Not Exclude Pump Thrombosis in Left Ventricular Assist Devices by Shelton, Julie, DO et al.
  
 
 
The VAD Journal: http://dx.doi.org/10.13023/VAD.2016.15 Page 1 of 7 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
Peer-Reviewed Case Report 
 
 
Normal Lactate Dehydrogenase Does 
Not Exclude Pump Thrombosis in Left 
Ventricular Assist Devices 
 
Julie Shelton*, Bennet George, Amanda Hart, and Maya Guglin 
 
University of Kentucky, Lexington, KY 
  
* Corresponding author: jsh253@uky.edu 
 
Abstract 
 
Left ventricular assist device (LVAD) pump thrombosis is a well-known 
complication of LVAD placement. Elevated lactate dehydrogenase (LDH) has 
classically been the first objective marker of pump thrombosis. In this case, we 
present a patient found to have normal serum LDH values but was ultimately found 
to have significant pump thrombosis. 
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Introduction 
 
Pump thrombosis is a well-known complication of left ventricular assist device 
(LVAD).  Elevated lactate dehydrogenase (LDH) has classically been the first and 
most consistent objective marker of this condition. In this case, we present a 
patient with completely normal serum LDH values who was ultimately found to 
have pump thrombosis. 
Case Presentation 
A 64-year-old gentleman with a Heartware HVAD left ventricular assist device 
(LVAD) initially presented to an outside emergency department with progressive 
fatigue, melena for one week, along with an abrupt drop in the flow rate noted on 
his device’s controller. His LVAD was placed two years prior to presentation in the 
setting of chronic systolic heart failure secondary to ischemic cardiomyopathy.  
The patient’s home anticoagulation regimen consisted of aspirin 81 mg daily and 
warfarin titrated to a target INR of 1.5-1.8. In the year and a half since 
implantation, he experienced multiple episodes of gastrointestinal bleeding and 
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underwent multiple endoscopic procedures, including eight colonoscopies. The 
procedures were unrevealing with no overt source of bleeding identified.  While he 
had felt fatigued over one week, he acutely felt worse on the day of presentation.  
Furthermore, the patient noticed that the flow on his LVAD controller dropped from 
4.5 L/min to less than 1 L/min. On review of systems, the patient mentioned he 
had recurrence of melena over the last week. Subsequent interrogation of his 
LVAD in the emergency room confirmed flows less than 1 L/min as well as absent 
pulsatility on the flow waveform.  He was found to be anemic and two units of 
packed red blood cells along with 1 L of intravenous fluids was administered.  A 
continuous dopamine infusion was started for hypotension.  The patient was 
transferred to our institution for further care. 
On arrival, the patient was in mixed cardiogenic and hypovolemic shock in the 
setting of gastrointestinal bleeding. He was afebrile with a heart rate of 70 
beats/min and a blood pressure of 92/75 mmHg.  Laboratory data revealed a 
hemoglobin of 6.7 g/dL with a hematocrit of 21.1%, platelet count of 254 k/µL, INR 
of 2.0, serum creatinine of 1.79 mg/dL (baseline of 0.7 mg/dL), serum lactate 
dehydrogenase (LDH) of 195 U/L (institutional reference range: 116-250 U/L), and 
plasma free hemoglobin (pfHb) less than 3 mg/dL. LDH was checked repeatedly, 
and remained within normal limits.  
Over next several days, the patient became anuric with worsening serum 
creatinine.  He was referred for right heart catheterization to assess intracardiac 
hemodynamics.  Elevated right and left-sided filling pressures were seen with a 
right atrial pressure of 20 mmHg, a pulmonary artery pressure of 74/29 mmHg 
(mean 46 mmHg), and a pulmonary capillary wedge pressure of 27 mmHg. Mixed 
venous oxygen saturation was 43%.  Transthoracic echocardiography 
demonstrated an ejection fraction of 20-30% with moderate to severe hypokinesis 
of the left ventricle. His aortic valve opened with each beat.  
Despite adequate volume resuscitation, including blood products, and the 
escalation to three vasopressors, the patient’s LVAD flows remained low at about 
2 L/min.  We attempted to increase the pump speed to 3000 revolutions per 
minute (rpms) but this did not result in a flow increase.  Despite a normal hemolytic 
work-up, our suspicion for pump thrombosis remained high.  Cardiothoracic 
surgery was consulted and the patient was taken to the operating room for LVAD 
exchange.  The hardware was found to have complete inflow and outflow 
thrombus occlusion as well as thrombus within the left ventricle (Figure 1).  
Figure 2 demonstrates the changes in intracardiac hemodynamics prior to and 
shortly after pump exchange.  Right atrial pressures decreased from an average of 
22 mmHg for the 14 hours prior to surgery to 16 mmHg in the 19 hours after 
surgery.  Similarly, pulmonary artery systolic pressures ranged from 84-104 mmHg 
preoperatively and improved to a range of 49-68 mmHg after pump exchange.   
LVAD flows improved and the patient was able to be weaned off of all 
vasopressors.  Figure 3 demonstrates the normalization of his serum creatinine as 
his urine output increased and acute kidney injury resolved. The red arrow 
indicates the pump exchange. 
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Figure 1: Inflow cannula demonstrating complete thrombosis. 
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The patient’s hospital course was complicated by sustained ventricular tachycardia 
requiring defibrillation as well as postoperative respiratory insufficiency with a left 
pleural effusion requiring decortication.  His gastrointestinal bleeding resolved 
without intervention.  He was later transplanted with no complications. 
Discussion 
The use of left ventricular assist devices (LVADs) is increasing in the management 
of refractory end-stage heart failure1-2.  As LVAD technology improves, there has 
been a reduction in adverse events; however, pump thrombosis remains a life-
threatening complication3-4.  The advantages of continuous flow LVADs are the 
lower incidence of bleeding complications as well as the reduced rates of infection 
when compared to pulsatile flow LVADs.  Unfortunately, the challenges of pump 
thrombosis, gastrointestinal bleeding, and aortic insufficiency persist3-4.  In a 
multicenter study, Starling et al. documented an increase in the rate of device 
thrombosis in patients receiving the HeartMate II LVAD when compared to the pre-
approval clinical trials.  In the last two years of the study, their group found that the 
occurrence of pump thrombosis increased from 2.2% to 8.4% at three months 
post-implantation10.  Multiple other studies cite rates of confirmed pump 
thrombosis between 0.9-14%3-12.  Early detection and a high index of suspicion for 
these complications are critical, as thromboembolic events and pump thrombosis 
carry significant morbidity and mortality3,9-10.  
Pump thrombosis is defined as clot within the flow path in any portion of the LVAD 
device and should be suspected with clinical signs of heart failure, abnormal pump 
parameters (such as sustained power spikes), elevated LDH, or clinical signs or 
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symptoms of hemolysis 5, 11-12.  The rise in LDH usually precedes a pump 
thrombosis event, and routine monitoring is indicated to allow for early recognition 
of possible pump thrombosis3.  Cowger et al. have shown that an elevated LDH 
was associated with increased adverse events in LVAD patients, and LDH 
monitoring parameters may allow for earlier detection of pump thrombosis.  In the 
setting of hemolysis, elevations in LDH may occur as many as 4 months before 
changes in pfHb with clinical signs of hemolysis11.  Guidelines from the 
International Society for Heart and Lung Transplantation recommend to follow 
biologic markers for hemolysis as a sign of thrombosis13.  Akin et al. report a 
sensitivity and specificity of LDH greater than three times the upper limit of normal 
of 88% and 97%, respectively12.  Similarly, Uriel et al. found that an LDH greater 
than four times the upper limit of normal was 100% sensitive and 92.5% specific 
for pump thrombosis at the time of diagnosis9.  Of note, a study by Shah, et al 
found that LDH levels associated with centrifugal (e.g. Heartware) LVADs are, in 
general, lower than with axial flow (e.g. HeartMate II) LVADs. Not only did they 
show LDH was more sensitive for pump thrombosis than pfHb, but extrapolation of 
their data indicated that a lower threshold of LDH elevation may be required to 
evaluate for pump thrombosis in Heartware LVADs14. Thus, LDH has been shown 
to be an important adjunct in early diagnosis of LVAD-related thrombosis.  
After an extensive literature review, this is the first case report we have come 
across where there was no clear evidence of hemolysis appreciated prior to 
confirmed pump thrombosis.  Our patient, in fact, had an LDH and plasma free 
hemoglobin within the normal limits of our laboratory values.  He did have 
evidence of pump failure given minimal flow upon LVAD interrogation, as well as 
clinical signs of heart failure evidenced by worsening pulmonary and peripheral 
edema, anuria, and worsening intracardiac hemodynamics.   Given such a clear 
clinical picture of LVAD pump failure, our index of suspicion for pump thrombosis 
remained high.  Ultimately, the fact that this patient had normal hemolysis 
biomarkers in the setting of significant pump thrombosis suggests that we must 
question the sensitivity of LDH as an early detector of this significant complication.  
Hemolysis occurs due to mechanical damage to red blood cells (RBCs).  Turbulent 
flow and high shear stress on RBCs, especially during periods of hemodynamic 
instability, contribute to hemolysis.  Heat generation as well as the rough, textured 
surfaces of the device may also play a role5,7-8.  All of these factors rely on blood 
flow through the pump in order for mechanical damage to RBCs to occur. In our 
patient, the complete occlusion of the pump meant he had no blood flow through 
his device and, therefore, no cellular damage or hemolysis.  While he did have a 
pump thrombosis leading to pump failure, hemolysis biomarkers were not helpful 
in the diagnosis.  The diagnosis of pump thrombosis can be challenging, but in a 
patient with pump failure and clinical evidence of worsened heart failure it must 
remain on the differential. 
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